Catalysts for $AZN
72 tracked
Sep 23, 2024
approval
TRUQAP (CAPIVASERTIB) โ FDA approval
capivasertib
โ
Aug 22, 2024
approval
BEYFORTUS (NIRSEVIMAB-ALIP) โ FDA approval
nirsevimab
โ
Aug 15, 2024
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Jul 24, 2024
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Jun 14, 2024
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Jun 5, 2024
approval
CALQUENCE (ACALABRUTINIB) โ FDA approval
CALQUENCE
โ
Jun 5, 2024
approval
CALQUENCE (ACALABRUTINIB MALEATE) โ FDA approval
CALQUENCE
โ
Apr 22, 2024
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Feb 23, 2024
approval
BEYFORTUS (NIRSEVIMAB-ALIP) โ FDA approval
nirsevimab
โ
Jan 24, 2024
approval
KOSELUGO (SELUMETINIB SULFATE) โ FDA approval
selumetinib sulfate
โ
Dec 21, 2023
approval
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) โ FDA approval
eplontersen sodium
โ
Dec 20, 2023
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Nov 16, 2023
approval
TRUQAP (CAPIVASERTIB) โ FDA approval
capivasertib
โ
Jul 17, 2023
approval
BEYFORTUS (NIRSEVIMAB-ALIP) โ FDA approval
nirsevimab
โ
Jun 16, 2023
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
May 26, 2023
approval
TEZSPIRE (TEZEPELUMAB-EKKO) โ FDA approval
tezepelumab
โ
Feb 1, 2023
approval
TEZSPIRE (TEZEPELUMAB-EKKO) โ FDA approval
tezepelumab
โ
Nov 10, 2022
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Oct 21, 2022
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Sep 2, 2022
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Aug 3, 2022
approval
CALQUENCE (ACALABRUTINIB MALEATE) โ FDA approval
CALQUENCE
โ
Aug 3, 2022
approval
CALQUENCE (ACALABRUTINIB MALEATE) โ FDA approval
CALQUENCE
โ
May 11, 2022
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Mar 24, 2022
approval
CALQUENCE (ACALABRUTINIB) โ FDA approval
CALQUENCE
โ
Dec 22, 2021
approval
KOSELUGO (SELUMETINIB SULFATE) โ FDA approval
selumetinib sulfate
โ
Dec 17, 2021
approval
TEZSPIRE (TEZEPELUMAB-EKKO) โ FDA approval
tezepelumab
โ
Jul 15, 2021
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Feb 19, 2021
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Nov 18, 2020
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ
Nov 18, 2020
approval
IMFINZI (DURVALUMAB) โ FDA approval
ASTRAZENECA PLC
โ